Which has the lower trailing P/E, HUM or TEVA?

HUM has the lower trailing P/E: HUM trades at 37.18 and TEVA at 62.70. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, HUM or TEVA?

Over the past five years, HUM grew revenue faster — HUM at a 12.61% CAGR versus TEVA at 1.19%.

Does HUM or TEVA pay a bigger dividend?

HUM pays a dividend (0.90% yield), while TEVA is a former payer with no current dividend run rate.

Is HUM or TEVA more profitable?

TEVA runs the higher net margin — HUM at 0.88% versus TEVA at 4.08%.

How have HUM and TEVA total returns compared?

Over the past 10 years, HUM delivered 9.19% and TEVA delivered -2.70% annualized total return. Past performance doesn't predict future results.

Humana Inc. (HUM) vs Teva Pharmaceutical Industries Limited (TEVA)

A side-by-side comparison of Humana Inc. and Teva Pharmaceutical Industries Limited across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of August 28, 2026. Differences are shown without an overall score or investment verdict.

HUM

Humana Inc.

$46.89B

$390.52HealthcareDelayed quote: Aug 28, 2026, 12:20 PM EDT

TEVA

Teva Pharmaceutical Industries Limited

$42.66B

$36.63HealthcareDelayed quote: Aug 28, 2026, 12:20 PM EDT

Total return — HUM vs TEVA

growth of $100 · dividends reinvested · last 10y

HUM +142.5% (+9.3%/yr)TEVA -23.5% (-2.6%/yr)HUM compounded faster over this window

HUM TEVA

HUM vs TEVA: by the numbers

•HUM is the larger company ($46.89B vs $42.66B market cap).
•HUM trades at the lower trailing earnings multiple (37.18 vs 62.70 P/E), one valuation lens rather than an overall verdict.
•TEVA converts more revenue to profit (4.08% vs 0.88% net margin).
•HUM grew revenue faster over the past five years (12.61% vs 1.19% CAGR).
•HUM pays a dividend (0.90% yield), while TEVA is a former payer with no current dividend run rate.

Metrics side by side

Valuation

Metric	HUM	TEVA
P/E ratio	37.18	62.70
Forward P/E	42.89	18.80
P/S ratio	0.33	2.57
P/B ratio	2.47	5.73
EV / EBITDA	19.77	19.40
FCF yield	N/A	3.03%

Profitability

Metric	HUM	TEVA
Gross margin	13.65%	52.47%
Operating margin	1.39%	11.45%
Net margin	0.88%	4.08%
ROE	6.65%	9.10%
ROIC	4.52%	6.79%

Dividends

Metric	HUM	TEVA
Dividend yield	0.90%	N/A
Payout ratio	35.87%	N/A

Growth (annualized)

Metric	HUM	TEVA
Revenue CAGR (5Y)	12.61%	1.19%
EPS CAGR (5Y)	-17.27%	N/A
FCF CAGR (5Y)	-17.19%	14.58%
Total return CAGR (5Y)	0.34%	32.11%

Frequently asked

Which has the lower trailing P/E, HUM or TEVA?: HUM has the lower trailing P/E: HUM trades at 37.18 and TEVA at 62.70. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, HUM or TEVA?: Over the past five years, HUM grew revenue faster — HUM at a 12.61% CAGR versus TEVA at 1.19%.
Does HUM or TEVA pay a bigger dividend?: HUM pays a dividend (0.90% yield), while TEVA is a former payer with no current dividend run rate.
Is HUM or TEVA more profitable?: TEVA runs the higher net margin — HUM at 0.88% versus TEVA at 4.08%.
How have HUM and TEVA total returns compared?: Over the past 10 years, HUM delivered 9.19% and TEVA delivered -2.70% annualized total return. Past performance doesn't predict future results.

Go deeper

Full HUM analysis Full TEVA analysis Interactive comparison tool

Dig into the metrics

Humana P/E ratio Teva Pharmaceutical Industries P/E ratio Humana dividend yield Humana ROE Teva Pharmaceutical Industries ROE Humana operating margin Teva Pharmaceutical Industries operating margin Humana revenue growth Teva Pharmaceutical Industries revenue growth Humana free cash flow Teva Pharmaceutical Industries free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified August 28, 2026.